Abbott Laboratories revenue by year
Over the 10 fiscal years shown, revenue went from $20.85B (year ended Dec 31, 2016) to $44.33B (year ended Dec 31, 2025), a compound annual growth rate of 8.7%. The fastest growth was +31.3% in the year ended Dec 31, 2017; the weakest year was −8.1% (year ended Dec 31, 2023).
Annual revenue
| Fiscal year ended | Revenue (USD) | Change | XBRL concept | Reported in |
|---|---|---|---|---|
| Dec 31, 2025 | $44.33B | +5.7% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 20, 2026 |
| Dec 31, 2024 | $41.95B | +4.6% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 20, 2026 |
| Dec 31, 2023 | $40.11B | −8.1% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 20, 2026 |
| Dec 31, 2022 | $43.65B | +1.3% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 21, 2025 |
| Dec 31, 2021 | $43.08B | +24.5% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 16, 2024 |
| Dec 31, 2020 | $34.61B | +8.5% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 17, 2023 |
| Dec 31, 2019 | $31.90B | +4.3% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 18, 2022 |
| Dec 31, 2018 | $30.58B | +11.6% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 19, 2021 |
| Dec 31, 2017 | $27.39B | +31.3% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 21, 2020 |
| Dec 31, 2016 | $20.85B | +2.2% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 22, 2019 |
Quarterly revenue
Quarters reported in 10-Q filings. Fourth quarters are usually reported only inside the annual 10-K, so they are not listed separately here; we do not estimate them.
| Quarter | Revenue (USD) | vs same quarter a year earlier | Source |
|---|---|---|---|
| 3 months ended Mar 31, 2026 | $11.16B | +7.8% | 10-Q filed Apr 29, 2026 |
| 3 months ended Sep 30, 2025 | $11.37B | +6.9% | 10-Q filed Oct 29, 2025 |
| 3 months ended Jun 30, 2025 | $11.14B | +7.4% | 10-Q filed Jul 30, 2025 |
| 3 months ended Mar 31, 2025 | $10.36B | +4.0% | 10-Q filed Apr 29, 2026 |
| 3 months ended Sep 30, 2024 | $10.63B | +4.9% | 10-Q filed Oct 29, 2025 |
| 3 months ended Jun 30, 2024 | $10.38B | +4.0% | 10-Q filed Jul 30, 2025 |
| 3 months ended Mar 31, 2024 | $9.96B | +2.2% | 10-Q filed Apr 30, 2025 |
| 3 months ended Sep 30, 2023 | $10.14B | −2.6% | 10-Q filed Oct 31, 2024 |
Source: SEC EDGAR XBRL company facts for CIK 1800 (raw data). Most recent filing in this dataset: 10-Q filed Apr 29, 2026. SEC data file dated Nov 3, 2026; page built Nov 5, 2026. Figures are as most recently reported, including restatements. How we select figures.